StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Trading Up 1.4 %
RDHL stock opened at $2.80 on Friday. The firm has a 50 day moving average of $4.77 and a 200-day moving average of $6.89. RedHill Biopharma has a 12-month low of $2.47 and a 12-month high of $20.28.
Institutional Trading of RedHill Biopharma
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC purchased a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is owned by hedge funds and other institutional investors.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Read More
- Five stocks we like better than RedHill Biopharma
- 3 Best Fintech Stocks for a Portfolio Boost
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Business Services Stocks Investing
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
